The Expression of MicroRNA-155 in Plasma and Tissue Is Matched in Human Laryngeal Squamous Cell Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Tumor-associated microRNAs have been detected in cancer, though whether plasma microRNA-155 (miR-155) could be a potential biomarker for laryngeal squamous cell carcinoma (LSCC) prognosis is unclear. We aimed to determine how miR-155 can be used to predict the clinical characteristics of patients with LSCC and correctly diagnose them. Materials and Methods: We collected tissue samples and peripheral blood samples before and after treatment from 280 LSCC cases and 560 controls. Real-time quantitative reverse transcription PCR was employed in this study to compare the relative expressionof miR-155. Results: A total of 280 LSCC patients and 560 age- and sex-matched controls were included in the study. The miR-155 level was more up-regulated in LSCC tissue than in the non-tumor tissues (13.6±2.4 vs. 3.1±0.80, p<0.001). Additionally, a significantly higher miR-155 level in plasma samples from LSCC patients than in those of the controls (8.9±1.25 vs. 1.8±0.8, p<0.001) was reported. Tissue miR-155 showed an area under the curve (AUC) of 0.933, with a sensitivity of 82.6% and a specificity of 89.2%. The AUC for plasma miR-155 was 0.757, with a sensitivity of 58.4% and a specificity of 69.5%. When early LSCC in TNM I stage was considered, tissue miR-155 showed an area under the curve of 0.804, with a sensitivity of 85.2% and a specificity of 87.3%. Conclusion: The expression of tissue and plasma miR-155 were significantly up-regulated in patients with LSCC. Our work will serve as a basis for further investigation, preferably large-scale validation in clinical trials.
Abstract
Purpose: Tumor-associated microRNAs have been detected in cancer, though whether plasma microRNA-155 (miR-155) could be a potential biomarker for laryngeal squamous cell carcinoma (LSCC) prognosis is unclear. We aimed to determine how miR-155 can be used to predict the clinical characteristics of patients with LSCC and correctly diagnose them. Materials and Methods: We collected tissue samples and peripheral blood samples before and after treatment from 280 LSCC cases and 560 controls. Real-time quantitative reverse transcription PCR was employed in this study to compare the relative expressionof miR-155. Results: A total of 280 LSCC patients and 560 age- and sex-matched controls were included in the study. The miR-155 level was more up-regulated in LSCC tissue than in the non-tumor tissues (13.6±2.4 vs. 3.1±0.80, p<0.001). Additionally, a significantly higher miR-155 level in plasma samples from LSCC patients than in those of the controls (8.9±1.25 vs. 1.8±0.8, p<0.001) was reported. Tissue miR-155 showed an area under the curve (AUC) of 0.933, with a sensitivity of 82.6% and a specificity of 89.2%. The AUC for plasma miR-155 was 0.757, with a sensitivity of 58.4% and a specificity of 69.5%. When early LSCC in TNM I stage was considered, tissue miR-155 showed an area under the curve of 0.804, with a sensitivity of 85.2% and a specificity of 87.3%. Conclusion: The expression of tissue and plasma miR-155 were significantly up-regulated in patients with LSCC. Our work will serve as a basis for further investigation, preferably large-scale validation in clinical trials.
참고문헌 (36)
- Gourin CG, "Short- and long-term outcomes of laryngeal cancer care in the elderly", Laryngoscope, 125, pp.924~933 (2015)
- Landry D, "Squamous cell carcinoma of the upper aerodigestive tract: a review", Radiol Clin North Am, 53, pp.81~97 (2015)
- Rutt AL, "Laryngeal cancer in patients younger than 30 years: a review of 99 cases", Ear Nose Throat J, 89, pp.189~192 (2010)
- Park JM, "The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma", Hum Pathol, 41, pp.431~437 (2010)
- Qiu G, "Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma", Med Oncol, 31, pp.316~ (2014)
- Vasca V, "Keratin 5 expression in squamocellular carcinoma of the head and neck", Oncol Lett, 8, pp.2501~2504 (2014)
- Cheng CJ, "MicroRNA silencing for cancer therapy targeted to the tumour microenvironment", Nature, 518, pp.107~110 (2015)
- Loh YH, "Evolution of microRNAs and the diversification of species", Genome Biol Evol, 3, pp.55~65 (2011)
- Ceppi P, "MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells", Oncogene, 33, pp.269~278 (2014)
- Xu TP, "MicroRNA-155expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas", Asian Pac J Cancer Prev, 14, pp.7085~7090 (2013)
- Lind EF, "Mir-155, a central modulator of T-cell responses", Eur J Immunol, 44, pp.11~15 (2014)
- Zheng Y, "Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory response by downregulating microRNA-155: a novel anti-inflammation mechanism", Free Radic Biol Med, 52, pp.1307~1317 (2012)
- Bera A, "A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer", PLoS One, 9, pp.e106343~ (2014)
- Chen L, "miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy", Exp Ther Med, 8, pp.527~532 (2014)
- Pareek S, "MiR-155 induction in microglial cells suppresses Japanese encephalitis virus replication and negatively modulates innate immune responses", J Neuroinflammation, 11, pp.97~ (2014)
- Zhu J, "Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10", PLoS One, 7, pp.e46551~ (2012)
- Anzi S, "Transcriptional repression of c-Jun’s E3 ubiquitin ligases contributes to c-Jun induction by UV", Cell Signal, 20, pp.862~871 (2008)
- Tutar Y, "miRNA and cancer; computational and experimental approaches", Curr Pharm Biotechnol, 15, pp.429~ (2014)
- Ayaz L, "Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma", J Cancer Res Clin Oncol, 139, pp.1499~1506 (2013)
- Sun X, "MicroRNA expression and its detection in human supraglottic laryngeal squamous cell carcinoma", Biomed Rep, 1, pp.743~746 (2013)
- Wu TY, "MiR19a is correlated with prognosis and apoptosis of laryngeal squamous cell carcinoma by regulating TIMP-2 expression", Int J Clin Exp Pathol, 7, pp.56~63 (2013)
- Jones K, "Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma", Clin Cancer Res, 20, pp.253~264 (2014)
- Vimalraj S, "Regulation of breast cancer and bone metastasis by microRNAs", Dis Markers, 35, pp.369~387 (2013)
- Gao F, "Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients", Oncol Rep, 31, pp.351~357 (2014)
- Hui AB, "Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas", Clin Cancer Res, 16, pp.1129~1139 (2010)
- Gasparini P, "microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers", Oncotarget, 5, pp.1174~1184 (2014)
- Kopp KL, "Expression of miR-155 and miR-126 in situ in cutaneous T-cell lymphoma", APMIS, 121, pp.1020~1024 (2013)
- Sochor M, "Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR24 enable monitoring of early breast cancer in serum", BMC Cancer, 14, pp.448~ (2014)
- Sun J, "Overexpression of microRNA-155 predicts poor prognosis in glioma patients", Med Oncol, 31, pp.911~ (2014)
- Zhao XD, "Overexpression of miR-155promotes proliferation and invasion of human laryngeal squamous cell carcinoma via targeting SOCS1 and STAT3", PLoS One, 8, pp.e56395~ (2013)
- Xu L, "The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer", BMC Cancer, 14, pp.714~ (2014)
- Zhang R, "MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers", Med Oncol, 31, pp.243~ (2014)
- Herberth G, "Maternal and cord blood miR-223 expression associates with prena-tal tobacco smoke exposure and low regulatory T-cell numbers", J Allergy Clin Immunol, 133, pp.543~550 (2014)
- Basso K, "BCL6 positively regulates AID and germinal center gene expression via repression of miR-155", J Exp Med, 209, pp.2455~2465 (2012)
- Sandhu SK, "miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model", Proc Natl Acad Sci U S A, 109, pp.20047~20052 (2012)
- Eis PS, "Accumulation of miR-155 and BIC RNA in human B cell lymphomas", Proc Natl Acad Sci U S A, 102, pp.3627~3632 (2005)